NEW YORK (GenomeWeb News) – Goldman Sachs today initiated coverage of Genomic Health with a Neutral rating and a six-month price target on its stock of $36.

In a research note, analyst Isaac Ro noted the growth potential of the Redwood City, Calif.-based firm's new products, but said that costs associated with those products will offset growth. Additionally, the company faces increased competition as well as a murky regulatory environment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.